Understanding pharmacy spending by heart failure (HF) patients requires an evaluation of the complex interactions between members, payers, and manufacturers in Part D. Part D spending by HF patients is higher than for other patients due to their condition and related comorbidities. The portions of spending attributable to the member, pharmaceutical manufacturer, Part D plan, and federal government can vary dramatically.
This report was commissioned by Novartis Pharmaceuticals Corporation.